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Background: Hyperemesis gravidarum is a serious condition affecting 0.8–2.3 % of pregnant women and can be
regarded as a restricted period of famine. Research concerning potential long-term consequences of the condition
for the offspring, is limited, but lack of nutrition in-utero has been associated with chronic disease in adulthood,
including some cancers. There is growing evidence that several forms of cancer may originate during fetal life. We
conducted a large study linking the high-quality population-based medical birth- and cancer registries in Norway,
Sweden and Denmark, to explore whether hyperemesis is associated with increased cancer risk in offspring.
Methods: A registry-based nested case–control study. Twelve types of childhood cancer were selected; leukemia,
lymphoma, cancer of the central nervous system, testis, bone, ovary, breast, adrenal and thyroid gland, nephroblastoma,
hepatoblastoma and retinoblastoma. Conditional logistic regression models were applied to study associations
between hyperemesis and risk of childhood cancer, both all types combined and separately. Cancer types with five
or more exposed cases were stratified by age at diagnosis. All analysis were adjusted for maternal age, ethnicity and
smoking, in addition to the offspring’s Apgar score, placental weight and birth weight. Relative risks with 95 %
confidence intervals were calculated.
Results: In total 14,805 cases and approximately ten controls matched on time, country of birth, sex and year of birth
per case (147,709) were identified. None of the cancer types, analyzed combined or separately, revealed significant
association with hyperemesis. When stratified according to age at diagnosis, we observed a RR 2.13 for lymphoma
among adolescents aged 11–20 years ((95 % CI 1.14–3.99), after adjustment for maternal ethnicity and maternal age, RR
2.08 (95 % CI 1.11–3.90)). The finding was not apparent when a stricter level of statistical significance was applied.
Conclusions: The main finding of this paper is that hyperemesis does not seem to increase cancer risk in offspring.
The positive association to lymphoma may be by chance and needs confirmation.
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Hyperemesis gravidarum is characterized by severe nausea
and vomiting during early pregnancy resulting in maternal
weight loss, nutritional deficiencies and hospital admis-
sions [1]. Little is known of the underlying causes and
consequences of the condition. Genetic, hormonal as well* Correspondence: kafv@fhi.no
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roles [2]. Previous research has primarily focused on
short-term outcomes associated with hyperemesis, with
inconsistent associations demonstrated for preterm birth,
low birth weight and risk of offspring small for gestational
age [3]. Two recent, large studies based on Norwegian
registry data, demonstrated no clinically significant impact
of hyperemesis on birth outcomes [4-6]. However, individ-
ual studies have reported that hyperemesis may have a
long-term impact on disease patterns later in life, includ-
ing increased risk of hypertension and reduced insulinal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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hood Cancer Study (UKCCS) found a 3.5-fold increase in
risk for all forms of leukemia among offspring of mothers
with severe hyperemesis [6], and an American study re-
ported that hyperemesis was associated with a four-fold
increase in testicular cancer risk among male offspring [7].
The fetal programming hypothesis suggests that ad-
verse exposures during critical periods of embryonic
development, in particular the first trimester, may per-
manently alter disease-susceptibility in later life [8].
Lack of nutrition is identified as key negative stimulus,
which may cause changes in the fetal circulation, pri-
oritizing essential growth (brain sparing) at the ex-
pense of other organs and tissues, or in the epigenome
of the fetus. These adaptive mechanisms may have
long-term impact on the functioning of these organs
and biological systems, resulting in increased suscepti-
bility to diseases in adulthood. For example, several
studies have demonstrated that maternal starvation in-
creases the risk of non-communicable diseases in adult-
hood of the offspring, such as hypertension, glucose-
intolerance, coronary heart disease and some forms of
cancer [9-11]. These long-term effects of exposure to
starvation in fetal life are irrespective of birth weight
[11], which suggests that even short-term nutritional
deprivation is important. Although relatively rare, the
incidence of cancer among children and adolescents is
increasing and is in many countries the leading cause of
disease-related death in this age-group [12]. Only a
small percentage of these cancers are caused by an
inherited genetic mutation, suggesting that cancer risk
in this group is under influence of many modifiable risk
factors. These factors may act through epigenetic path-
ways during fetal development [13].
Hyperemesis is a severe complication occurring in
early pregnancy that in many ways mimics starvation
thereby providing a model to explore the consequences
of under nutrition during a critical period of fetal de-
velopment. Specific hormonal alterations related to
hyperemesis may also influence epigenetic mechanisms
affecting the offspring’s susceptibility to other diseases,
such as cancer. Given the sparse data on associations
between maternal hyperemesis and cancer risk in off-
spring, large, population-based studies based on data
collected in a standardized protocol are needed. The
aim of this study was therefore to investigate whether
hyperemesis is associated with cancer in the offspring,
using merged national medical birth- and cancer regis-
tries in Norway, Sweden and Denmark.
Methods
This nested case–control study is based on pooled
data from population-based registries in each of the
Scandinavian countries. The unique identification numberassigned to all citizens in these countries at birth or upon
immigration was used to link the medical birth registries
(MBRs) to the national cancer registries. The MBRs in
Norway, Sweden and Denmark, founded in 1967, 1973
and 1977, respectively, are based on mandatory report-
ing of all births on standardized forms, completed by
the attending midwife or physician shortly after birth
and supplemented by the antenatal health card and
hospital records. The MBRs contain information on
maternal background, pregnancy and birth, and selected
short-term outcomes for the offspring. The Scandinavian
cancer registries, established in 1943 (Denmark), 1951
(Norway) and 1957 (Sweden), are also population-based,
with mandatory reporting of all incident tumors. Data in
these registries have been reported to be complete and of
high quality [14-18].
For the Norwegian and Swedish data, information on
maternal country of birth was obtained from Statistics
Norway and Statistics Sweden, respectively. In Denmark,
demographic variables were obtained from the Civil
Registration System. Information on smoking habits be-
came available in Sweden in 1982, in Denmark in 1991
and in Norway in 1999. For Apgar scores, information
was available in Sweden in 1972, in Denmark in 1978
and in Norway in 1976. Placental weight was available in
Sweden during 1982–1999, in Denmark in 1997 and in
Norway in 1999. Because these data became available at
different times in the three countries, the number of
missing values is relatively high in our study.
Our study included the twelve most common types of
cancer in childhood and adolescence, defined according
to the 10th edition of the International Classification
of Disease (ICD-10); leukemias (C91-95), lymphomas
(C81-C85), tumors of the brain and nervous system
(C70-72 and D42-43), breast, females only (C50), bone
(C40-C41), testis (C62), ovary (C56), thyroid gland
(C73), adrenal gland (C74), retinoblastoma (C69.2),
Wilms’ tumor (C64.9) and hepatoblastoma (C22). Cases
were Scandinavian children and adolescents registered in
the MBRs at birth, diagnosed with one of the above types
of cancer before the age of 21 years and registered in the
corresponding National Cancer Registry. The first 21 years
of life were selected to focus primarily on the potential ef-
fect of perinatal exposure. Only singletons born between
23–43 weeks of gestation, and only primary cases of can-
cers were included.
For each case, we sampled up to ten controls who
were cancer-free at time of diagnosis for the case, and
matched by birth registry, sex and year of birth. Children
with Downs’s syndrome were excluded as they are
known to be at higher risk for several types of cancer.
In Sweden, hyperemesis was defined through ICD-8
codes 638.0 and 638.9 until 1987, ICD-9 code 643 until
1997 and subsequently with ICD-10 code O21, O21.1
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from the National Patient Registry (NPR) to increase the
validity of the diagnosis. In Norway and Denmark,
hyperemesis was defined through ICD-8 codes until
ICD-10 codes were available. In Denmark, information
on hyperemesis was gathered from the NPR, while in
Norway this information was obtained from the MBR
solely.
Maternal country of birth, smoking (smoker/non-
smoker) and age (in five-year age-groups) were consid-
ered as possible confounders, and adjusted for, as were
placental weight (less than 500, 500–999 and equal to or
heavier than 1000 g and missing), birth weight (less than
1500, 1500–2499, 2500–3499, 3500–3999, 4000–4499
and birth weights equal to or above 4500 g and missing)
and Apgar score (at one and five mins; equal to or below
seven or higher than seven and missing). In line with
previous research on hyperemesis, maternal country of
birth was categorized into six immigrant groups that
were culturally and geographically related.
Conditional logistic regression models were used to
study associations between hyperemesis and all selected
types of childhood cancer. The models were stratified by
age for each cancer type with five or more exposed
cases. The regression models were adjusted by maternal
age, ethnicity and smoking, in addition to offspring’s
Apgar score, placental weight and birth weight. We then
implemented a backward elimination procedure, remov-
ing explanatory variables one by one and observing if
the estimate changed. Crude and adjusted relative risks
(RR) were calculated with 95 % confidence intervals
(CI). Due to multiple testing, we performed the analyses
with 99 % confidence intervals as well, for selected can-
cer types. SPSS for Windows version 20.0 (SPSS Inc.,
Chicago, IL, USA) was used for all analyses.
The study was approved by the Danish Data Protec-
tion Agency (record no 2008-41-2767) and the Regional
Ethical Board in Stockholm, Sweden and the Regional
Ethical Committee in Oslo, Norway.
Results
Demographic variables for mothers and offspring are
presented in Table 1. Ninety-seven (0.7 %) cases were
exposed to hyperemesis during pregnancy. A high per-
centage of missing values was observed for maternal
smoking, placental weight and Apgar score after one
and five mins: 77.4 %, 80.0 % and 16.3/14.1 %, respect-
ively. Neither maternal nor fetal variables differed sub-
stantially between cases and controls.
Leukemia was the most common type of childhood
cancer, comprising almost 35 % of the cases (n = 5114),
followed by tumors of the central nervous system
(30.6 %) and lymphoma (12.5 %). Cancers of the breast,
testis, thyroid and ovary were more common in theoldest age group, while tumors of the adrenal gland,
nephroblastoma and retinoblastoma were more frequent
among the youngest age-groups (Table 2). Leukemia was
most common under 11 years of age, while lymphoma
peaked among adolescents and young adults. In total,
63 % of cases were between 0 and 10 years old at time
of diagnosis.
No association between hyperemesis and childhood
cancer was observed for all selected cancer types com-
bined (Table 3). This was unchanged after adjustment
for maternal age and country of birth. For cancers of the
breast, bone, testis, ovary, thyroid and adrenal gland, in
addition to retinoblastoma and hepatoblastoma, fewer
than five cases each had been exposed to hyperemesis.
When the model was stratified according to age at
diagnosis for the remaining cancer types (Table 4), a sig-
nificant association between hyperemesis and lymphoma
was observed in offspring aged 10–20 years (RR = 2.13
(95 % CI: 1.14–3.99)), which was not observed in the
younger age-group. Adjustment for potential confounders
did not significantly change the estimate (RR = 2.08 (95 %
CI: 1.11–3.90)). None of the other selected cancer types
were significantly associated with maternal hyperemesis.
When applying an alpha-level of 0.01, the risk of lymph-
oma in the highest age-group was no longer statistically
significant; RR 2.13 (99 % CI: 0.93–4.85) and aRR 2.08
(99 % CI: 0.91–4.45) (results not shown in table).
Discussion
In this study, the main results displayed no association
between hyperemesis and cancer risk in offspring. This is
reassuring news for women suffering from hyperemesis,
which is the most common cause of hospital admissions
in early pregnancy. However, in the age group 10–20 years
we observed a significant positive association between
hyperemesis and lymphoma. As we performed multiple
analyses, we explored the association with stricter criteria
for statistical significance. Our main finding was not sig-
nificant at an alpha-level of 0.01. Further investigation on
the impact of offspring’s age, revealed that only the oldest
adolescents in the highest age-group were at increased
risk. The potential effect of adverse perinatal exposure be-
comes more difficult to isolate from later environmental
influences with increasing age of the offspring. This war-
rants caution in the interpretation of the findings. How-
ever, according to the hypothesis of fetal programming,
adverse exposure in-utero may increase an individual’s
vulnerability for disease in adulthood, co-acting with en-
vironmental exposures. Despite the pooling of data from
Scandinavia, the numbers of cases exposed to hyperemesis
was still low, limiting the ability to detect significant asso-
ciations. Stratifying by birth registry, the same positive
tendency regarding lymphoma risk was observed both in
Sweden and Norway. In Denmark there were not enough
Table 1 Demographic characteristics of all mothers, mothers of
cases and mothers of controls, and birth outcomes for all
offspring, for cases and controls
Cases (%) Controls (%) Total
Maternal country of birth
Europe, USA, Canada 14.102 (95.3) 139.949 (94.7) 154,051
Middle-East* 262 (1.8) 2.732 (1.8) 2.994
Africa excluding
North-Africa
77 (0.5) 823 (0.6) 900
Asia** 155 (1.0) 1.897 (1.3) 2.052
Central and
South-America
105 (0.7) 1.085 (0.7) 1.190
Other countries and
missing
104 (0.7) 1.223 (0.8) 1.327
Maternal age, in years
<20 601 (4.1) 6.227 (4.2) 6.828
20–24 3.423 (23.1) 35.446 (24.0) 38.869
25–29 5.385 (36.4) 53.690 (36.3) 59.075
30–34 3.716 (25.1) 36.561 (24.8) 40.277
>34 1.680 (11.3) 15.785 (10.7) 17.465
Smoking***
Nonsmoker 2.042 (13.8) 21.011 (14.2) 23.053
Smoker 1.264 (8.5) 12.418 (8.4) 13.682
Missing 11.499 (77.7) 114.280 (77.4) 125.779
Hyperemesis status
HG + 97 (0.7) 818 (0.6) 915
HG - 14.708 (99.3) 146.891 (99.4) 161.599
Birth weight (gr)
<1500 97 (0.7) 1.021 (0.7) 1.118
1500–2499 549 (3.7) 5.602 (3.8) 6.151
2500–3499 6.046 (40.8) 63.972 (43.3) 70.018
>3500 8.067 (54.5) 76.771 (52.0) 84.838
Missing 46 (0.3) 343 (0.2) 389
Placental weight
(gr)****
<500 411 (2.8) 4.177 (2.8) 4.588
500–999 2.492 (16.8) 24.872 (16.8) 27.364
≥1000 112 (0.8) 929 (0.8) 1.041
Missing 11.790 (79.6) 117.731 (79.7) 129.521
Apgar score after
1 min*****
< 7 659 (4.5) 5.597 (3.8) 6.256
≥ 7 11.760 (79.4) 117.986 (79.9) 129.746
Missing 2.386 (16.1) 24.126 (16.3) 26.512
Table 1 Demographic characteristics of all mothers, mothers of
cases and mothers of controls, and birth outcomes for all
offspring, for cases and controls (Continued)
Apgar score after
5 min*****
< 7 161 (1.1) 1.400 (0.9) 1.561
≥ 7 12.558 (84.8) 125.480 (85.0) 138.038
Missing 2.086 (14.1) 20.829 (14.1) 22.915
Total 14.805 147.709 162.514
*Middle-East includes Turkey, Lebanon, Syria, Palestine, Iraq, Morocco, Algeria,
Tunisia, Libya, Egypt, Iran
**Asia includes Pakistan, India, Sri-Lanka, Vietnam, Thailand, Philippines, China,
South-Korea, Japan
***Available from 1991 in Denmark, 1999 in Norway and 1982 in Sweden
****Available from 1997 in Denmark, 1999 in Norway and in for the years
1982–1999 in Sweden
*****Available from 1991 in Denmark, 1999 in Norway and 1982 in Sweden
Numbers in parentheses indicate percentage distributions within the categories
of each variable among all offspring, among cases and among controls
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the long-term consequences of hyperemesis for the off-
spring is limited, these findings warrant further research
on the topic.
There is increasing evidence that several sub-types of
hematological malignancies can originate in-utero
[19,20]. Single studies have also reported increased risk
of cancer in offspring following hyperemesis exposure.
In the United Kingdom Childhood Cancer Study (UKCCS),
a positive association was reported between severe hyper-
emesis and acute lymphatic leukemia and acute myeloid
leukemia with an OR of 3.6 (95 % CI: 1.3-10.1). For non-
Hodgkin’s lymphoma an OR of 6.8 was reported, but the
association did not reach the level of statistical significanceTable 2 Number of cases and age at diagnosis according to
cancer type. Numbers in parentheses indicate percentage
distributions among age categories for each cancer type
Type of cancer Age at diagnosis
0–10 11–20 N
Leukemia 4.114 (80.4) 1.000 (19.6) 5.114
Central nervous system 3.003 (66.4) 1.521 (33.6) 4.524
Lymphoma 491 (26.5) 1.362 (73.5) 1.853
Testis 154 (18.2) 693 (81.8) 847
Nephroblastoma 422 (95.7) 19 (4.3) 441
Adrenal gland 386 (92.6) 31 (7.4) 417
Primary bone 163 (41.4) 231 (58.6) 394
Retinoblastoma 344 (99.7) 1 (0.3) 345
Thyroid gland 35 (10.2) 308 (89.8) 343
Ovary 67 (22.6) 229 (77.4) 296
Hepatoblastoma 172 (80.8) 41 (19.2) 213
Breast 1 (5.6) 17 (94.4) 18
Total 9.352 (63.2) 5.453 (36.8) 14.805
Table 3 Relative risk (RR) of cancer in offspring according to maternal hyperemesis gravidarum (HG)- status for selected types of
cancer combined and separately, with 95 % confidence intervals (95 % CI)
N Cases Controls Crude RR (95 % CI) Adjusted RR* (95 % CI)
Total 14.805 HG+ 97 HG+ 818 1.18 (0.95-1.46) 1.19 (0.97-1.48)
HG- 14.708 HG- 146.891
Leukemia 5.114 HG+ 28 HG+ 280 0.99 (0.67-1.47) 1.00 (0.68-1.48)
HG-5.086 HG- 50.845
Central nervous 4.524 HG+ 29 HG+ 242 1.20 (0.81-1.78) 1.24 (0.84-1.83)
system HG- 4.495 HG- 45.026
Lymphoma 1.853 HG+ 15 HG+ 102 1.70 (0.98-2.96) 1.68 (0.97-2.92)
HG- 1.838 HG- 19.973
Testis 847 HG+ 4 HG+ 51 0.87 (0.31-2.43) 0.87 (0.31-2.43)
HG- 843 HG- 9.190
Nephroblastoma 441 HG+ 8 HG+ 48 1.97 (0.91-4.23) 2.01 (0.93-4.34)
HG- 433 HG- 4.850
Adrenal gland 417 HG+ 3 HG+ 28 1.12 (0.34-3.75) 1.14 (0.34-3.80)
HG- 414 HG- 4.567
Primary bone 394 HG+ 2 HG+ 15 1.40 (0.31-6.20) 1.38 (0.31-6.15)
HG-392 HG- 4.286
Retinoblastoma 345 HG+ 3 HG+ 36 0.97 (0.29-3.20) 0.97 (0.29-3.20)
HG- 342 HG- 3.725
Thyroid gland 343 HG+ 4 HG+ 21 2.11 (0.71-6.29) 2.21 (0.73-6.71)
HG- 339 HG- 3.836
Ovary 296 HG+ 1 HG+ 20 0.50 (0.07-3.72) 0.48 (0.06-3.62)
HG- 295 HG- 3.193
Hepatoblastoma 213 HG+ 0 HG+ 13 - -
HG- 213 HG- 2.340
Breast 18 HG+ 0 HG+ 2 - -
HG- 18 HG- 187
*Adjusted for maternal age and maternal country of birth
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cifically designed to explore perinatal risk factors for child-
hood cancer. However, the number of exposed cases was
low, with only eight cases in total. Based on 28 exposed
leukemia cases, we did not observe any such association.
How hyperemesis may increase the risk of lymphoma
is a matter of speculation. Lymphoma has been linked to
fetal growth and low birth weight [22]. The association
of hyperemesis with low birth weight has been inconsist-
ent [3,5,6], possibly because the maternal hunger-period
is short, causing any weight loss early in pregnancy to be
compensated for in the remaining weeks. Also, efficient
treatment may secure fetal growth. However, the general
environment in utero could still be adversely affected
[11]. Previous studies exploring the effect of famine ex-
posure confined to early pregnancy have reported nega-
tive outcomes for long-term health regardless of birth
weight [11,23,24].The underlying biology behind the programming of
cancer susceptibility in-utero is unknown but is likely
to involve epigenetic mechanisms. Epigenetics refer to
any change to the genome which does not include al-
terations in the nucleotide sequence. DNA methylation
and histone modification are two important epigenetic
mechanisms by which the gene expression may be
modified [25]. The epigenetic changes may affect dif-
ferent regulatory pathways such as the production of
stem cells or hormones, which may alter organogenesis
[13]. DNA methylations have been observed in several
steps of carcinogenesis [26]. It has also been suggested
that nutritional restriction may cause changes to the
fetal blood circulation, sparing the brain at the expense
of other organs and tissues during a “window of vul-
nerability” in fetal development. Altered perfusion
patterns may result in long-term increased disease
susceptibility.
Table 4 Relative risk (RR) of cancer in offspring according to maternal hyperemesis gravidarum (HG)- status for selected types of
cancer combined and separately for the most common types according to age at diagnosis, with 95 % confidence intervals (95 % CI)
Cancer type Age at diagnosis, in years Crude RR (95 % CI) Adjusted RR* (95 % CI)*
All selected cancer forms
n = 9.352 0–10 1.16 (0.90–1.51) 1.18 (0.91–1.53)
n = 5.453 11–20 1.21 (0.84–1.74) 1.21 (0.84–1.74)
Leukemia
n = 4.114 0–10 1.07 (0.70–1.64) 1.08 (0.71–1.65)
n = 1.000 11–20 0.70 (0.25–1.93) 0.70 (0.25–1.93)
Central nervous system
n = 3.003 0–10 1.18 (0.74–1.89) 1.22 (0.76–1.94)
n = 1.521 11–20 1.27 (0.63–2.56) 1.27 (0.62–2.56)
Lymphoma
n = 491 0–10 0.95 (0.29–3.12) 0.94 (0.28–3.10)
n = 1.362 11–20 2.13 (1.14–3.99) 2.08 (1.11–3.90)
Nephroblastoma
n = 422 0–10 2.02 (0.94–4.35) 2.06 (0.95–4.45)
n = 19 11–20 – –
*Adjusted for maternal age and maternal country of birth
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several studies have suggested that elevated levels of
estrogen and human chorionic gonadotropin (hCG) are
important risk factors [27,28]. hCG can act as a growth
factor and is associated with placental- and germ cell-
cancers in particular, but subtypes of the molecule are
believed to be produced in most advanced malignancies
[29,30]. During pregnancy, estrogen levels are more than
ten times higher than normal, and can be even higher
among women with hyperemesis. Pregnancies with a
female or multiple fetuses both have been associated
with higher levels of estrogen as well as higher risk of
hyperemesis [27,31,32]. Estrogens may be oncogenic to
hematopoietic cells, and some studies have shown an as-
sociation between estrogen exposure and leukemia [33].
It is not known whether the same association exists be-
tween hyperemesis and lymphoma.
As risk of breast cancer has been linked to estrogen
exposure in-utero [34], offspring born to hyperemetic
mothers may also be at increased risk. While we did not
find such an association, we only followed offspring to
age 21. Given that breast cancer has a median - age of
incidence of about 60 years in western countries [35],
our dataset was not appropriate for studying a possible
association between in-utero exposure to hyperemesis
and subsequent breast cancer. At the same time, with
age it becomes more difficult to distinguish the bio-
logical from the environmental impacts on cancer risk.
In addition, as the MBRs were founded in the 1960s,
the majority of offspring have yet to enter higher risk
age-group.In contrast to findings of an American study of 131
men with testicular cancer, we found no association
between hyperemesis and risk of testicular cancer in
offspring [36]. However, this study dating back to 1979,
was small and included only eight cases of testicular
cancer following a hyperemetic pregnancy. To our
knowledge, such an association has not been reported
since. Testicular cancer in childhood is rare and differs
histologically, genetically and etiologically from that
observed in adolescence and adulthood [37]. The con-
dition has been associated with both a high ponderal
index and high birth weight, suggesting links between
childhood testicular cancer, the intrauterine environ-
ment and fetal growth. As in the case of breast cancer,
inclusion of older age-groups of cases might have
yielded interesting findings. Still, it would have been
difficult to isolate the effect of the intrauterine envir-
onment on risk of these cancers.
The major strength of this study is its large sample
size, resulting from collaboration between the three
Scandinavian countries. As well, merging population-
based registries provided a relatively high number of
cases making selection bias therefore unlikely and in-
creasing the generalizability of our results. Registration
of hyperemesis was performed prior to development of
cancer in the offspring, which eliminated the risk of
recall-bias. The MBRs offer extensive information on
maternal and fetal variables making it possible to con-
trol for more potential confounders than earlier studies.
Differences in the MBRs pose potential limitations. An
important example is high numbers of missing values
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However, a previous study on hyperemesis and risk of
short-term adverse outcomes for offspring, using the
Norwegian MBR, included sub-analysis specifically ex-
ploring the possible impact of smoking on risks associ-
ated with hyperemesis, with no change in the observed
associations [5]. Although different ICD-codes were
used at different time-points to register hyperemesis,
clinically relevant cases are most likely to have been
included, regardless of ICD version. Moreover, the
prevalence of hyperemesis among controls was relatively
low compared to earlier estimates, possibly due to under-
reporting of mild hyperemesis to the birth- and patient
registries, the latter requiring hospital admission. It could
also reflect the lack of a general consensus regarding the
correct definition of the condition.
Another possible limitation is that information on
severity and onset of hyperemesis was unavailable. How-
ever, widely used definitions of hyperemesis, including
the one applied by the ICD-10, pinpoints time of onset
before the end of 22nd week of gestation. Previous re-
search has shown that the majority of women experience
hyperemesis during the first and second trimesters [38].
The validity of hyperemesis registration in the MBR has
been explored in Norway, but not in Denmark or
Sweden. In Norway, investigators reported a sensitivity
and specificity of 83.9 % and 96.0 % respectively - satis-
factory validity for large-scale epidemiological studies. A
risk of misclassification of hyperemesis was also re-
ported, which could result in registration of fewer cases
of severe hyperemesis. This may in turn weaken ob-
served associations of exposure and outcome [39].
Conclusion
We found no association between hyperemesis and the
over-all or site-specific risk of cancer in offspring, except
for a suggested increase in lymphoma in adolescence
and early adulthood. The latter finding may be due to
chance and requires validation in other studies.
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